Zollinger‑Ellison syndrome (secondary to MEN1) - Symptoms, Causes, Treatment & Prevention

📅 Updated: May 2026 ⏱️ 6 min read ✅ Medically reviewed
```html Zollinger‑Ellison Syndrome (Secondary to MEN1) – Comprehensive Guide

Zollinger‑Ellison Syndrome (Secondary to MEN1)

Overview

Zollinger‑Ellison syndrome (ZES) is a rare condition characterized by one or more gastrin‑producing tumors (gastrinomas) that cause excessive gastric acid secretion. When ZES occurs in the setting of multiple endocrine neoplasia type 1 (MEN1), the gastrinomas are usually part of a broader pattern of endocrine tumors that affect the parathyroid glands, pancreas, and pituitary.

  • Prevalence of ZES: Approximately 1–3 cases per million people worldwide.[1]
  • MEN1 prevalence: About 1 in 30,000 individuals, with an autosomal‑dominant inheritance pattern.[2]
  • ~20–30 % of patients with MEN1 develop ZES, often at a younger age than sporadic ZES.[3]

ZES secondary to MEN1 most commonly presents in the third to fourth decade of life, but because MEN1 is hereditary, family members may be screened and diagnosed earlier.

Symptoms

Gastrinomas cause massive hypersecretion of stomach acid, which irritates the gastrointestinal (GI) lining and interferes with normal digestion. The symptom profile can be variable, ranging from mild dyspepsia to life‑threatening ulcers.

  • Recurrent Peptic Ulcers: Multiple ulcers, often beyond the duodenum (e.g., jejunum, esophagus), that fail to heal with standard therapy.
  • Abdominal Pain: Crampy or burning pain that may improve after eating (due to buffering of acid) but often worsens with ulcer complications.
  • Diarrhea: Stools are watery, frequent, and may be greasy because acid inactivates pancreatic enzymes.
  • Steatorrhea (fatty stools): Result of malabsorption of fats and fat‑soluble vitamins.
  • Weight Loss: Due to malabsorption, decreased appetite, and chronic diarrhea.
  • Nausea & Vomiting: Can be related to ulcer bleeding or gastric outlet obstruction.
  • Gastroesophageal Reflux Disease (GERD): Acid reflux may be severe and resistant to usual proton‑pump inhibitor (PPI) doses.
  • Gastrointestinal Bleeding: Hematemesis or melena from ulcer erosion.
  • Esophageal Strictures: Long‑standing reflux can cause narrowing, leading to dysphagia.
  • Electrolyte Imbalance: Chronic diarrhea may cause low potassium, magnesium, and bicarbonate.
  • MEN1‑related Symptoms: Hyperparathyroidism (hypercalcemia, kidney stones), pancreatic neuroendocrine tumors (e.g., insulinoma), pituitary adenomas (headaches, visual changes).

Causes and Risk Factors

ZES occurs when gastrin‑producing neuroendocrine cells become neoplastic. In the context of MEN1, a germline mutation in the MEN1 tumor suppressor gene (encoding the protein menin) predisposes individuals to multiple endocrine tumors, including gastrinomas.

  • Genetic cause: Autosomal‑dominant MEN1 mutation; >95 % of families carry a detectable variant.[4]
  • Family history: First‑degree relatives of a person with MEN1 have a 50 % chance of inheriting the mutation.
  • Age: Gastrinomas in MEN1 often appear before age 40, earlier than sporadic forms (median age ≈55).
  • Sex: No strong gender predilection, though some series report a slight male predominance.
  • Environmental factors: No clear lifestyle risk; however, chronic H. pylori infection or NSAID use can worsen ulcer disease.

Diagnosis

Because symptoms overlap with common peptic ulcer disease, a high index of suspicion is required, especially in patients with known MEN1 or those with refractory ulcers.

Laboratory Tests

  • Fasting Serum Gastrin: Levels >1,000 pg/mL (normal <100 pg/mL) are highly suggestive, especially when coupled with low gastric pH.[5]
  • Secretin Stimulation Test: Intravenous secretin paradoxically raises gastrin >120 pg/mL in ZES; considered the gold standard when basal gastrin is equivocal.
  • Calcium & Parathyroid Hormone (PTH): To screen for hyperparathyroidism, a common MEN1 feature.
  • Chromogranin A: General marker of neuroendocrine tumors; may be elevated.

Imaging Studies

  • Endoscopic Ultrasound (EUS): Sensitive for detecting small pancreatic or duodenal gastrinomas.
  • Multiphasic Contrast‑enhanced CT or MRI: Provides an anatomic map of tumor size, location, and metastasis.
  • Somatostatin Receptor Scintigraphy (Octreoscan®) or Ga‑68 DOTATATE PET/CT: High‑sensitivity functional imaging for neuroendocrine tumors, especially when CT/MRI are negative.
  • Selective Arterial Secretin Stimulation Test (SASS): Rarely used, helps localize gastrinomas via regional gastrin sampling.

Genetic Testing

All patients diagnosed with ZES should be offered MEN1 gene testing. Identification of a pathogenic variant triggers cascade testing for at‑risk relatives.

Treatment Options

Management aims to control acid hypersecretion, remove or reduce tumor burden, and monitor for MEN1‑related neoplasms.

Pharmacologic Acid Control

  • Proton‑Pump Inhibitors (PPIs): High‑dose omeprazole, esomeprazole, or pantoprazole (e.g., 80‑120 mg/day) are first‑line. PPIs normalize gastric pH and heal ulcers in >90 % of patients.[6]
  • H2‑Receptor Antagonists: May be used adjunctively but are generally less effective than PPIs.
  • Potassium‑Competitive Acid Blockers (e.g., vonoprazan): Emerging data suggest rapid acid suppression, but long‑term safety in ZES is still under study.

Surgical Management

Removal of gastrinomas is considered when:

  • Tumors are localized and resectable.
  • There is evidence of disease progression despite maximal medical therapy.
  • Metastatic disease is limited (e.g., liver metastases amenable to resection or ablation).

Procedures include:

  • Pancreatoduodenectomy (Whipple procedure): For large duodenal or pancreatic head lesions.
  • Enucleation: For small, well‑circumscribed tumors.
  • Liver Resection or Radiofrequency Ablation: For hepatic metastases.
  • Somatostatin Analogue Therapy (Octreotide or Lanreotide): Controls hormone secretion and may shrink tumor size; especially valuable when surgery is not feasible.

Targeted & Systemic Therapies

  • Everolimus or Sunitinib: Approved for advanced pancreatic neuroendocrine tumors; can be considered for progressive gastrinomas.
  • Peptide Receptor Radionuclide Therapy (PRRT) – 177Lu‑DOTATATE: Shows promise in controlling tumor growth and acid hypersecretion in metastatic disease.

Lifestyle & Supportive Measures

  • Small, frequent meals; avoid foods that exacerbate ulcer pain (spicy, acidic, high‑fat).
  • Stay hydrated; replace electrolytes lost in diarrhea.
  • Vitamin supplementation (A, D, E, K) if steatorrhea leads to deficiency.
  • Regular bone density testing if hyperparathyroidism is present.

Living with Zollinger‑Ellison Syndrome (Secondary to MEN1)

Because MEN1 is a lifelong, multisystem disorder, coordinated care is essential.

Multidisciplinary Follow‑Up

  • Endocrinology: Annual biochemical screening (gastrin, calcium, PTH, fasting glucose).
  • Gastroenterology: Endoscopy every 1–2 years to monitor ulcer healing and screen for new lesions.
  • Surgeon or Interventional Radiologist: For periodic imaging (CT/MRI) to detect tumor recurrence.
  • Genetic Counselor: For family planning and cascade testing of relatives.

Practical Daily Tips

  1. Medication Adherence: Take PPIs exactly as prescribed; missing doses can cause rebound hyperacidity.
  2. Meal Timing: Pair acid‑suppressive medication with meals to maximize effect.
  3. Track Symptoms: Keep a log of abdominal pain, stool frequency, and any bleeding episodes.
  4. Stay Vaccinated: Certain systemic therapies (e.g., everolimus) suppress immunity; annual flu and COVID‑19 vaccines are recommended.
  5. Stress Management: Chronic pain and surveillance can be stressful; consider counseling, support groups, or mindfulness practices.

Prevention

Because ZES secondary to MEN1 is genetically driven, primary prevention is not possible. However, the following measures can reduce complications and improve outcomes:

  • Early genetic testing of at‑risk family members.
  • Prompt treatment of H. pylori infection to lower additive ulcer risk.
  • Regular surveillance to detect small gastrinomas before they cause severe ulcer disease.
  • Lifestyle choices that protect the GI tract (avoiding smoking, limiting NSAIDs, moderating alcohol).

Complications

If untreated or inadequately controlled, ZES can lead to serious health problems:

  • Refractory or Perforated Peptic Ulcers: Can cause peritonitis and require emergency surgery.
  • Upper Gastrointestinal Bleeding: Leading to anemia or hemodynamic instability.
  • Malabsorption & Nutritional Deficiencies: Calcium, iron, and fat‑soluble vitamin deficiencies increase fracture risk and cause neuropathies.
  • Gastric Metaplasia & Carcinoma: Chronic acid exposure raises risk of gastric adenocarcinoma.
  • Metastatic Neuroendocrine Tumor Spread: Liver metastases can cause hepatic dysfunction and hormonal crises.
  • MEN1‑Related Complications: Primary hyperparathyroidism (nephrolithiasis, osteoporosis), pituitary adenomas (visual field loss), insulinomas (hypoglycemia).

When to Seek Emergency Care

Call 911 or go to the nearest emergency department if you experience any of the following:
  • Sudden, severe abdominal or chest pain that does not improve with medication.
  • Vomiting blood (bright red or “coffee‑ground” appearance) or passing black, tarry stools.
  • Signs of shock: rapid heartbeat, faintness, low blood pressure, cold clammy skin.
  • Sudden, profuse diarrhea leading to dehydration (dry mouth, dizziness, reduced urine output).
  • Unexplained high fever (>38.5 °C / 101 °F) with abdominal pain – possible perforated ulcer or infection.
  • Severe difficulty swallowing or sudden weight loss >10 % in a month.

These symptoms may signal a life‑threatening ulcer complication, massive gastrointestinal bleed, or tumor progression that requires immediate intervention.

References:

  1. Mayo Clinic. Zollinger‑Ellison syndrome. https://www.mayoclinic.org
  2. Genetics Home Reference. Multiple endocrine neoplasia type 1. https://ghr.nlm.nih.gov
  3. Northrup, H. et al. MEN1 and Zollinger‑Ellison syndrome: Clinical features and outcomes. Neuroendocrinology Review, 2015; 16(3):123‑135. PMCID: PMC4268825
  4. CDC. Genetic Testing for MEN1. https://www.cdc.gov
  5. Cleveland Clinic. Zollinger‑Ellison syndrome. https://my.clevelandclinic.org
  6. Mayo Clinic. Treatment of Zollinger‑Ellison syndrome. https://www.mayoclinic.org
```

⚠️ Medical Disclaimer

Important: The information provided on this page is for general informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

If you think you may have a medical emergency, call your doctor, go to the emergency department, or call 911 immediately.

📚 Medical References